Defective Protein Folding and Aggregation as the Basis of Neurodegenerative Diseases: The Darker Aspect of Proteins

Cell Biochemistry and Biophysics

Volumn 61, Issue 2, 2011, Pages 237-250

  Naeem, Aabgeena ^a   Fazili, Naveed Ahmad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Aggregation; Conformational diseases; Molecular chaperones; Protein misfolding

Indexed keywords

PROTEIN;

ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; GENETICS; HUMAN; METABOLISM; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEOSTASIS DEFICIENCY; REVIEW;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEINS; PROTEOSTASIS DEFICIENCIES;

EID: 80955166037     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9200-x     Document Type: Review

References (138)

1. Onuchic, J. N., & Wolynes, P. G. (2004). Theory of protein folding. Current Opinion in Structural Biology, 14, 70-75.
2. Anfinsen, C. (1972). The formation and stabilization of protein structure. Biochemistry Journal, 128, 737-749.
3. Alexander, P. A., He, Y., Chen, Y., Orban, J., & Bryan, P. N. (2007). The design and characterization of two proteins with 88% sequence identity but different structure and function. Proceedings of the National Academy of Scences of the United States of America, 104, 11963-11968.
4. Barrick, D., Hughson, F. M., & Baldwin, R. L. (1994). Molecular mechanisms of acid denaturation The role of histidine residues in the partial unfolding of apomyoglobin. Journal of Molecular Biology, 237, 588-601.
5. Jaenicke, R. (1991). Protein folding: Local structure, domains, subunits, and assemblies. Biochemistry, 30, 3147-3161.
6. Naeem, A., Khan, A., & Khan, R. H. (2005). Partially folded intermediate state of concanavalin A retains its carbohydrate specificity. Biochemistry and Biophysics Research Communications, 331, 1284-1294.
7. Ballery, N., Desmadril, M., Minard, P., & Yon, J. M. (1993). Characterization of an intermediate in the folding pathway of phosphoglycerate kinase: Chemical reactivity of genetically introduced cysteinyl residues during the folding process. Biochemistry, 32, 708-714.
8. Matousschek, A., Serrano, L., Meiering, E. M., Bycroft, M., & Ferscht, A. R. (1992). The folding of an enzyme IV Structure of an intermediate in the refolding of barnase analyzed by a protein engineering procedure. Journal of Molecular Biology, 224, 837-845.
9. Naeem, A., Khan, K. A., & Khan, R. H. (2004). Characterization of a partially folded intermediate of papain induced by fluorinated alcohols at low pH. Archives of Biochemistry and Biophysics, 432, 79-87.
10. Goto, Y., & Nishikiori, S. J. (1991). Role of electrostatic repulsion in the acidic molten globule of cytochrome c. Journal of Molecular Biology, 222, 679-686.
11. Naeem, A., Ahmad, T., Muzaffar, M., Ahmad, S., & Saleemuddin, M. (2011). A partially folded state of ovalbumin at low pH tends to aggregate. Cell Biochemistry and Biophysics, 59, 29-38.
12. Beswick, H. T., & Harding, J. J. (1987). Conformational changes induced in lens alpha-and gamma crystallins by modification with glucose 6-phosphate Implications for cataract. Biochemistry Journal, 246, 761-769.
13. Vlassara, H., Bucala, R., & Striker, L. (1994). Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Laboratory Investigation, 70, 138-151.
14. Harding, J. J. (1985). Non enzymatic covalent post translational modification of proteins in vivo. Advances in Protein Chemistry, 37, 247-334.
15. Hardesty, B., & Kramer, G. (2001). Folding of a nascent peptide on the ribosome. Progress in Nucleic Acid Research and Molecular Biology, 66, 41-66.
16. Bukau, B., & Horwich, A. L. (1998). The Hsp70 and Hsp60 chaperone machines. Cell, 92, 351-366.
17. Hartl, F. U., & Hayer-Hartl, M. (2002). Molecular chaperones in the cytosol: From nascent chain to folded protein. Science, 295, 1852-1858.
18. Schiene, C., & Fischer, G. (2000). Enzymes that catalyse the restructuring of proteins. Current Opinion in Structural Biology, 10, 40-45.
19. Dobson, C. M. (2003). Protein folding and misfolding. Nature, 426, 884-890.
20. Rose, G., Fleming, P., Banavar, J., & Maritan, A. (2006). A backbone-based theory of protein folding. Proceedings of the National Academy of Sciences of the United States of America, 103, 166231-166233.
21. Ptitsyn, O. B. (1995). Molten globule and protein folding. Advances in Protein Chemistry, 47, 83-87.
22. Pande, V. S., & Rokhsar, D. S. (1998). Is the molten globule a third phase of proteins. Proceedings of the National Academy of Sciences of the United States of America, 95, 1490-1494.
23. Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience, 4, 49-60.
24. Davis, R., Dobson, C. M., & Vendruscolo, M. (2002). Determination of the structures of distinct transition state ensembles for a β-sheet peptide with parallel folding pathways. Journal of Chemical Physics, 117, 9510-9517.
25. Flynn, G. C., Pohl, J., Flocco, MT., & Rothman, J. E. (1991). Peptide-binding specificity of the molecular chaperone BiP. Nature, 353, 726-730.
26. Landry, S. J., Jordan, R., McMacken, R., & Gierasch, L. M. (1992). Different conformations for the same polypeptide bound to chaperones DnaK and GroEL. Nature, 355, 455-457.
27. Gething, M. J., & Sambrook, J. (1992). Protein folding in the cell. Nature, 355, 33-45.
28. Harti, F. U., Martin, J., & Neupert, W. (1992). Protein folding in the cell: The role of molecular chaperones Hsp70 and Hsp60. Annual Review of Biophysics and Biomolecular Structure, 21, 293-322.
29. Schmid, F. X. (1991). Catalysis and assistance of protein folding. Current Opinion in Structural Biology, 1, 36-41.
30. Uversky, V. N., & Fink, A. (Eds.). (2006). "Protein misfolding, aggregation and conformational diseases", Part A: Protein aggregation and conformational diseases, series: Protein Reviews, Vol. 4, p. 419.
31. Kelly, J. (1998). Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Current Opinion in Structural Biology, 8, 101-106.
32. Dobson, C. M. (2001). The structural basis of protein folding and its links with human disease. Philosophical Transactions of the Royal Society London B, 356, 133-145.
33. Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., et al. (1997). Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature, 385, 78-793.
34. Thomas, P. J., Qu, B. H., & Pedersen, P. L. (1995). Defective protein folding as a basis of human disease. Trends in Biochemical Sciences, 20, 456-459.
35. Castillo, V., & Ventura, S. (2009). Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases. PLoS Computational Biology, 5, 1-16.
36. Amaral, M. D. (2004). CFTR and chaperones processing and degradation. Journal of Molecular Neuroscience, 23, 41-48.
37. Pullara, F., & Emanuele, A. (2008). Early stages of β2-microglobulin aggregation and the inhibiting action of αB-crystallin. Proteins, 73, 1037-1046.
38. Sherman, M. Y., & Goldberg, A. L. (2001). Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron, 29, 15-32.
39. Kayed, R., Head, E., Thompson, J. L., et al. (2003). Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science, 300, 486-489.
40. Fandrich, M., & Dobson, C. M. (2002). The behaviour of poly amino acids reveals an inverse side chain effect in amyloid structure formation. EMBO Journal, 21, 5682-5690.
41. Smith, J. F., Knowles, T. P., Dobson, C. M., et al. (2006). Characterization of the nanoscale properties of individual amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 103, 15806-15811.
42. Makin, O. S., Sikorski, P., & Serpell, L. C. (2006). Diffraction to study protein and peptide assemblies. Current Opinion in Chemical Biology, 10, 417-422.
43. Tycko, R. (2003). Insights into the amyloid folding problem from solid-state NMR. Biochemistry, 42, 3151-3159.
44. Torok, M., Milton, S., Kayed, R., et al. (2002). Structural and dynamic features of Alzheimer's Aβ peptide in amyloid fibrils studied by site-directed spin labelling. Journal of Biological Chemistry, 277, 40810-40815.
45. Goldsbury, C., Kistler, J., Aebi, U., et al. (1999). Watching amyloid fibrils grow by time-lapse atomic force microscopy. Journal of Molecular Biology, 285, 33-39.
46. Serpell, L., Sunde, M., Benson, M., et al. (2000). The protofilament substructure of amyloid fibrils. Journal of Molecular Biology, 300, 1033-1039.
47. Jimenez, J. L., Guijarro, J. I., Orlova, E., et al. (1999). Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO Journal, 18, 815-821.
48. Jimenez, J. L., Tennent, G., Pepys, M. B., et al. (2001). Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. Journal of Molecular Biology, 311, 241-247.
49. Jimenez, J. L., Nettleton, E. J., Bouchard, M., et al. (2002). The protofilament structure of insulin amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 99, 9196-9201.
50. Eanes, E. D., & Glenner, G. G. (1968). X-ray diffraction studies on amyloid filaments. Journal of Histochemistry and Cytochemistry, 16, 673-677.
51. Sunde, M., & Blake, C. C. (1998). From the globular to the fibrous state: Protein structure and structural conversion in amyloid formation. Quarterly Review of Biophysics, 31, 1-39.
52. Thakur, K. A., & Wetzel, R. (2002). Mutational analysis of the structural organization of polyglutamine aggregates. Proceedings of the National Academy of Sciences of the United States of America, 99, 17014-17019.
53. Ross, C. A., Michelle, A., Poirier, M. A., Wanker, E. E., & Amzel, M. (2003). Polyglutamine fibrillogenesis: The pathway unfolds. Proceedings of the National Academy of Sciences of the United States of America, 100, 1-3.
54. Sabate, R., De Groot, N. S., & Ventura, S. (2010). Protein folding and aggregation in bacteria. Cellular and Molecular Life Sciences, 67, 2695-2715.
55. Uversky, V. N. (2009). Intrinsic disorder in proteins associated with neurodegenerative diseases. Frontier Bioscience, 14, 5188-5238.
56. Morimoto, R. I., & Santoro, M. G. (1998). Stress-inducible responses and heat shock proteins: New pharmacologic targets for cytoprotection. Nature Biotechnology, 16, 833-838.
57. Bukau, B., Weissmanand, J., & Horwich, A. (2006). Molecular chaperones and protein quality control. Cell, 125, 445-451.
58. Auluck, P. K., Chan, H. Y., Trojanowsk, J. Q., Lee, V. M., & Bonini, N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science, 295, 865-868.
59. Klucken, J., Shin, Y., Masliah, E., Hyman, B. T., & McLean, P. J. (2004). Hsp70 reduces alpha-synuclein aggregation and toxicity. Journal of Biological Chemistry, 279, 25497-25502.
60. Sakahira, H., Breuer, P., Hayer-Hartl, M. K., & Hartl, F. U. (2002). Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 99, 16412-16418.
61. De Jong, W. W., Leunissen, J. A., Leenen, P. J., Zweers, A., & Versteeg, M. (1988). Comparison with small heat shock proteins and Schistosoma egg antigen. Journal of Biological Chemistry, 263, 5141-5149.
62. Pauli, D., Tonka, C. H., Tissieres, A., & Arrigo, A. P. (1990). Tissue-specific expression of the heat shock protein HSP27 during Drosophila melanogaster development. Journal of Cell Biology, 111, 817-828.
63. Wagstaff, M. J., Collaco-Moraes, Y., Smith, J., De Belleroche, J. S., Coffin, R. S., & Latchman, D. S. (1998). Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. Journal of Biological Chemistry, 274, 5061-5069.
64. Benjamin, I. J., & McMillan, D. R. (1998). Stress (heat shock) proteins: Molecular chaperones in cardiovascular biology and disease. Circulation Research, 83, 117-132.
65. Bruey, J. M., Ducasse, C., Bonniaud, P., Ravagnan, L., Susin, S. A., Diaz-Latoud, C., et al. (2000). Hsp27 negatively regulates cell death by interacting with cytochrome c. Nature Cell Biology, 2, 645-652.
66. Rane, M. J., Pan, Y., Singh, S., Powell, D., Wu, W. R., & Cummins, T. (2003). Heat shock protein 27 controls apoptosis by regulating Akt activation. Journal of Biological Chemistry, 278, 27828-27835.
67. Wyttenbach, A., Sauvageot, O., Carmichael, J., Diaz-Latoud, C., Arrigo, A. P., & Rubinsztein, D. C. (2002). Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntington. Human Molecular Genetics, 11, 1137-1151.
68. Zourlidou, A., Payne Smith, M. D., & Latchman, D. S. (2004). HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. Journal of Neurochemistry, 88, 1439-1448.
69. Cuervo, A. M., Wong, E. S. P., & Martinez-Vicente, M. (2010). Protein degradation, aggregation and misfolding. Movement Disorders, 25, S49-S54.
70. Rubinsztein, D. C. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 780-786.
71. Pandey, U. B., Nie, Z., Batlevi, Y., et al. (2007). HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature, 447, 859-863.
72. Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005). HDAC6 and microtubules are required for autophagic degradation of aggregated Huntington. Journal of Biological Chemistry, 280, 40282-40292.
73. Cookson, M. R. (2005). The biochemistry of Parkinson's disease. Annual Review of Biochemistry, 74, 29-52.
74. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., & Minoshima, S. (1998). Mutations in the parldn gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
75. Shimura, H., Hattori, N., Kubo, S., Yoshikuni, K., Mizuno, Y., et al. (2000). Familial Parkinson's disease gene product, parkin, is an ubiquitin-protein ligase. Nature Genetics, 25, 302-305.
76. Sriram, S. R., Li, X., Ko, H. S., Kenny, K. K., Chung Wong, E., et al. (2005). The biochemistry of Parkinson's disease. Human Molecular Genetics, 14, 2571-2586.
77. Hampe, C., Ardila-Osorio, H., Fournier, M., Alexis, B., & Olga, C. (2006). Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Human Molecular Genetics, 15, 2059-2207.
78. Matsuda, N., Kitami, T., Suzuki, T., Mizuno, Y., Hattori, N., & Tanaka, K. (2006). Diverse effects pathogenic mutations of Parkin that catalyze multiple monoub- iquitylation in vitro. Journal of Biological Chemistry, 281, 3204-3209.
79. Lim, K. L., Chew, K. C., & Tan, J. M. (2009). Parkin mediates non-classical, proteasomal-independent ubiquitination of synphilin-466. Apoptosis, 14, 455-468.
80. Lim, K. L., Dawson, V. L., & Dawson, T. M. (2006). Parkin- mediated lysine 63-linked polyubiquitination: A link to Lewy Body formation. Neurobiology of Aging, 27, 524-529.
81. Thomas, P. J., Shenbagamurthi, P., Sondek, J., Hullihen, J. M., & Pedersen, P. L. (1992). The cystic fibrosis transmembrane conductance regulatoreffects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. Journal of Biological Chemistry, 267, 5727-5730.
82. Stewart Loh, N. (2010). The missing zinc: p53 misfolding and cancer. Metallomics, 2, 442-449.
83. Kereszturi, E., Szmola, R., Kukor, Z., et al. (2009). Hereditary pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: A novel disease mechanism. Human Mutation, 30, 575-582.
84. Garthwaite, J., Charles, S. L., & Chess-Williams, R. (1988). Endothelium derived relaxing factor release on activation of NMDA receptors suggests role as intracellular messenger in the brain. Nature, 336, 385-388.
85. Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., & snyder, S. H. (1991). Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature, 351, 714-718.
86. Uehara, T., Nakamura, T., Yao, D., Shi, Z. Q., et al. (2006). S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature, 441, 513-517.
87. Yao, D., Gu, Z., Nakamura, T., Shi, Z. Q., Ma, Y., et al. (2004). Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proceedings of the National Academy of Sciences of the United States of America, 101, 10810-10814.
88. Nakamura, T., & Lipton, S. A. (2007). Molecular mechanisms of nitrosative stress-mediated protein misfolding in neurodegenerative diseases. Cellular and Molecular Life Sciences, 64, 1609-1620.
89. Fukushima, N., Furuta, D., Hidaka, Y., Moriyama, R., & Tsujiuchi, T. (2009). Post translational modifications of tubulin in nervous system. Journal of Neurochemistry, 109, 683-693.
90. Gomes, R., Sousasilva, M., Quintas, A., Cordeiro, C., et al. (2005). Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochemical Journal, 385, 339-345.
91. Obrenovich, M. E., & Monnier, V. M. (2004). Glycation stimulates amyloid formation. Science of Aging Knowledge Environment, 2, 3.
92. Cohen, M. P., & Ziyadeh, F. N. (1996). Role of amadori-modified nonenzymatically glycated serum proteins. Journal of the American Society of Nephrology, 7, 183-190.
93. Bunn, H. F., & Higgins, P. J. (1981). Kinetic analysis of the non enzymatic glycosylation of hemoglobin. Journal of Biological Chemistry, 213, 222-224.
94. Chiti, F., & Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry, 75, 333-366.
95. Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science, 298, 789-791.
96. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297, 353-356.
97. Serpell, L. C., & Smith, J. M. (2000). Direct visualisation of the beta-sheet structure of synthetic Alzheimer's amyloid. Journal of Molecular Biology, 299, 225-231.
98. Esler, W. P., & Wolfe, M. S. (2001). A portrait of Alzheimer secretases-new features and familiar faces. Science, 293, 1449-1454.
99. Citron, M. (2002). Alzheimer's disease: Treatments in discovery and development. Nature Neuroscience, 5, 1055-1057.
100. Michael, P., Vitek, T., Bhattacharya, K. J., et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 91, 4766-4770.
101. Pike, C., Walencewicz, A., Glabe, C., & Cotman, C. (1991). In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. European Journal of Pharmacology, 207, 367-368.
102. Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993). Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. Journal of Neuroscience, 13, 1676-1687.
103. Forno, L. S. (1996). Neuropathology of Parkinson's disease. Journal of Neuropathology and Experimental Neurology, 55, 259-272.
104. Kruger, R., Kuhn, W., Muller, T., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics, 18, 106-108.
105. Polymeropoulos, M. H., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
106. Tetzlaff, J. E., Putcha, P., Outeiro, T. F., et al. (2008). CHIP targets toxic α-synuclein oligomers for degradation. The Journal of Biological Chemistry, 283, 17962-17968.
107. Trojanowski, J., & Lee, V. (1998). Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia. Archives of Neurology, 55, 151-152.
108. Ross, R. A., & Poirier, M. A. (2004). Protein aggregation and neurodegenerative diseases. Nature Medicine, 10, S10-S17.
109. Kirkwood, S. C., Su, J. L., Conneally, P., & Foroud, T. (2001). Progression of symptoms in the early and middle stages of Huntington disease. Archives of Neurology, 58, 273-278.
110. Davies, S. W., Turmaine, M., Cozens, B. A., et al. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-548.
111. Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., et al. (1999). Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology. Proceedings of the National Academy of Sciences of the United States of America, 96, 4604-4609.
112. Hoffner, G., & Djian, P. (2002). Protein aggregation in Huntington's disease. Biochimie, 84, 273-278.
113. Huang, C. C., Faber, P. W., Persichetti, F., et al. (1998). Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins. Somatic Cell and Molecular Genetics, 24, 217-233.
114. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D., & Housman, D. (1999). Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 96, 11404-11409.
115. Véronique, V. B., Hussein, D., Patrick, A. D., Edor, K., Rouleau Guy, A. R., & Paul, V. N. (2010). TDP-43, protein aggregation, and amyotrophic lateral sclerosis. US Neurology, 5, 35-38.
116. Hudson, A. J. (1981). Amyotrophic lateral sclerosis and its association with dementia, Parkinsonism and other neurological disorders: A review. Brain, 104, 217-247.
117. Strong, M. J., Volkening, K., Hammond, R., et al. (2007). TDP43 is a human low molecular weight neurofilament (hNFL) mRNAbinding protein. Molecular and Cellular Neuroscience, 35, 320-327.
118. Neumann, M., Sampathu, D. M., Kwong, L. K., et al. (2006). Ubiquitinated TDP-43 in fronto temporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.
119. Arai, T., Hasegawa, M., Akiyama, H., et al. (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications, 351, 602-611.
120. Mackenzie, I. R., Bigio, E. H., Ince, P. G., et al. (2007). Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology, 61, 427-434.
121. Crabbe, M. J. (1998). Cataract as a conformational disease: The Maillard reaction, alpha-crystallin and chemotherapy. Cellular and Molecular Biology, 44, 1047-1050.
122. Chen, Y. C., Reid, G. E., Simpson, R. J., & Truscott, R. J. (1997). Molecular evidence for the involvement of alpha crystallin in the coloration/crosslinking of crystallins in age related nuclear cataract. Experimental Eye Research, 65, 835-840.
123. Ecroyd, H., & Carver, J. A. (2009). Crystallin proteins and amyloid fibrils. Cellular and Molecular Life Sciences, 66, 62-81.
124. Meehan, S., Berry, Y., Luisi, B., Dobson, C. M., Carver, J. A., & MacPhee, C. E. (2004). Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. Journal of Biological Chemistry, 279, 3413-3419.
125. Zhang, J., Yan, H., Harding, J. J., Liu, Z. X., Wang, X., & Ruan, Y. S. (2008). Identification of the primary targets of carbamylation in bovine lens proteins by mass spectrometry. Current Eye Research, 33, 963-976.
126. Graw, J. (1999). Cataract mutations and lens development. Progress in Retinal and Eye Research, 18, 235-267.
127. Graw, J. (2009). Genetics of crystallins: Cataract and beyond. Experimental Eye Research, 88, 173-189.
128. Jung, J., Byeon, I. J., Wang, Y., King, J., & Gronenborn, A. M. (2009). The structure of the cataract-causing P23T mutant of human gamma d-crystallin exhibits distinctive local conformational and dynamic changes. Biochemistry, 48, 2597-2609.
129. Sandilands, A., Hutcheson, A. M., Long, H. A., et al. (2002). Altered aggregation properties of mutant g-crystallins cause inherited cataract. EMBO Journal, 21, 6005-6014.
130. Qu, B. H., Strickland, E., & Thomas, P. J. (1997). Cystic fibrosis: A disease of altered protein folding. Journal of Bioenergetics and Biomembranes, 29, 483-490.
131. Smith, J. J., Travis, S. M., Greenberg, E. P., & Welsh, M. J. (1996). Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell, 85, 229-236.
132. Pier, G. B., Grout, M., Zaidi, T. S., Olsen, J. C., Johnson, L. G., Yankaskas, J. R., et al. (1996). Role of mutant CFTR in hyper susceptibility of cystic fibrosis patients to lung infections. Science, 271, 64-67.
133. Quinton, P. M. (1990). Cystic fibrosis: A disease in electrolyte transport. FASEB Journal, 4, 2709-2717.
134. Thomas, P. J., et al. (1992). The cystic fibrosis transmembrane conductance regulator. Journal of Biological Chemistry, 267, 5727-5730.
135. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., et al. (2005). Inhibition of heparin-induced tau filament formation by phenotiazines, polyphenols, and porphyrins. Journal of Biological Chemistry, 280, 7614-7623.
136. De Felice, F., Houzel, J. C., Garcia-Abreu, J., Louzada, P., Afonso, R. C., & Meirelles, M. N. (2001). Inhibition of Alzheimer's disease-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: Implications for Alzheimer's therapy. FASEB Journal, 15, 1297-1299.
137. Raghu, P., Reddy, G. B., & Sivakumar, B. (2002). Inhibition of transthyretin amyloid fibril formation by 2, 4-dinitrophenol through tetramer stabilization. Archives of Biochemistry and Biophysics, 400, 43-47.
138. Polverino de Laureto, P., Taddei, N., Frare, E., Capanni, C., Costantini, S., Zurdo, J., Chiti, F., Dobson, C. M., & Fontana, A. (2003). Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis. Journal of Molecular Biology, 334, 129-141.